ORs in age-restricted cohort for 60-day mortality and secondary outcomes
| . | Model . | GLP1-RA vs. DPP4i use . | SGLT2i vs. DPP4i use . |
|---|---|---|---|
| 60-day mortality | Crude | 0.44 (0.34–0.56) | 0.45 (0.34–0.59) |
| TMLE | 0.59 (0.36–0.97) | 0.69 (0.52–0.92) | |
| IPTW | 0.52 (0.40–0.68) | 0.60 (0.44–0.80) | |
| Total mortality‡ | Crude | 0.44 (0.35–0.55) | 0.44 (0.33–0.57) |
| TMLE | 0.60 (0.38–0.96) | 0.67 (0.51–0.88) | |
| IPTW | 0.53 (0.41–0.69) | 0.58 (0.43–0.77) | |
| Emergency room visit§ | Crude | 0.79 (0.72–0.87) | 0.78 (0.70–0.87) |
| TMLE | 0.88 (0.74–1.04) | 0.95 (0.85–1.07) | |
| IPTW | 0.89 (0.80–1.00) | 0.90 (0.80–1.00) | |
| Hospitalization§ | Crude | 0.66 (0.60–0.73) | 0.66 (0.59–0.74) |
| TMLE | 0.80 (0.67–0.95) | 0.87 (0.77–0.98) | |
| IPTW | 0.83 (0.74–0.93) | 0.81 (0.72–0.91) | |
| Mechanical ventilation (intubation or ventilation)§ | Crude | 0.75 (0.63–0.89) | 0.79 (0.65–0.95) |
| TMLE | 0.77 (0.55–1.09) | 0.95 (0.77–1.17) | |
| IPTW | 0.79 (0.65–0.95) | 0.87 (0.71–1.07) |
| . | Model . | GLP1-RA vs. DPP4i use . | SGLT2i vs. DPP4i use . |
|---|---|---|---|
| 60-day mortality | Crude | 0.44 (0.34–0.56) | 0.45 (0.34–0.59) |
| TMLE | 0.59 (0.36–0.97) | 0.69 (0.52–0.92) | |
| IPTW | 0.52 (0.40–0.68) | 0.60 (0.44–0.80) | |
| Total mortality‡ | Crude | 0.44 (0.35–0.55) | 0.44 (0.33–0.57) |
| TMLE | 0.60 (0.38–0.96) | 0.67 (0.51–0.88) | |
| IPTW | 0.53 (0.41–0.69) | 0.58 (0.43–0.77) | |
| Emergency room visit§ | Crude | 0.79 (0.72–0.87) | 0.78 (0.70–0.87) |
| TMLE | 0.88 (0.74–1.04) | 0.95 (0.85–1.07) | |
| IPTW | 0.89 (0.80–1.00) | 0.90 (0.80–1.00) | |
| Hospitalization§ | Crude | 0.66 (0.60–0.73) | 0.66 (0.59–0.74) |
| TMLE | 0.80 (0.67–0.95) | 0.87 (0.77–0.98) | |
| IPTW | 0.83 (0.74–0.93) | 0.81 (0.72–0.91) | |
| Mechanical ventilation (intubation or ventilation)§ | Crude | 0.75 (0.63–0.89) | 0.79 (0.65–0.95) |
| TMLE | 0.77 (0.55–1.09) | 0.95 (0.77–1.17) | |
| IPTW | 0.79 (0.65–0.95) | 0.87 (0.71–1.07) |
Data are OR (95% CI). The age-restricted cohort included only individuals age 45–80 years (5,341 GLP1-RA users, 3,130 SGLT2i users, and 2,867 DPP4i users). TMLE: primary analysis. IPTW: sensitivity analysis.
During the observation period.
Within 14 days after a positive SARS-CoV-2 test.